Clinical significance of serum tumor markers for advanced gastric cancer with the first-line chemotherapy

Abstract

Background: Tumor markers play an important role in the diagnosis, monitoring and prognostic prediction of cancers. But the predictive value of serum tumor markers in gastric cancer is still unclear.Methods: In this study, we detected serum levels of tumor markers to evaluate their relation to treatment response and prognosis in patients with unresectable advanced or metastatic gastric cancer. Results: We collected the clinical data of 109 patients with unresectable advanced or metastatic gastric cancer who had received the first-line chemotherapy in Peking University Cancer Hospital from July 2013 to May 2015, and collected the value of serum carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), carbohydrate antigen 72.4 (CA72.4) and carbohydrate antigen 125 (CA125) before and after chemotherapy. At diagnosis, the positive rates of CEA, CA199, CA72.4 and CA125 were 46.8%, 40.2%, 53.5% and 35.0%, respectively. And the positive rate of combined detection of the four markers was 87.2%. Although patients with prechemotherapy CA199 ≥80 U/mL (92.3% vs. 68.5%, P=0.016) or CA72.4 ≥20 U/mL (91.4%vs. 62.5%, P=0.003) had higher clinical benefit rate after chemotherapy, they showed poorer prognosis (P=0.023 and P=0.006, respectively). CA72.4 ≥20 U/mL was an independent unfavorable prognostic factor (Hazard Ratio 4.84; 95% confidence interval: 1.910-12.262; P=0.001). In patients with increased levels of tumor markers before treatment, the levels of tumor markers decreased after chemotherapy, especially in those with clinical benefit (CEA, CA72.4 reached statistical significance, P=0.013 and P=0.029, respectively). A decrease of CEA ≥35%, CA199 ≥30%, or CA72.4 ≥40% after chemotherapy had positive prediction value for the response to chemotherapy (P=0.016, P=0.029, and P=0.008, respectively). Conclusions:The results showed that both high pre-chemotherapy serum levels of tumor markers (CA199 ≥80 U/mL or CA72.4 ≥20 U/mL) and a substantial decrease in tumor markers after chemotherapy (CEA ≥35%, CA199 ≥30%, or CA72.4 ≥40%) could predict a higher clinical benefit rate in patients with unresectable advanced or metastatic gastric cancer. However, this advantage in short-term response to chemotherapy failed to convert into prolonged survival benefits.

Crocin reverses 1-methyl-3-nitroso-1-nitroguanidine (MNNG)-induced malignant transformation in GES-1 cells through the Nrf2/Hippo signaling pathway

“…Crocin reverses 1-methyl-3-nitroso-1-nitroguanidine (MNNG)induced malignant transformation in GES-1 cells through the Nrf2/ mechanisms of which are still unclear. Due to poor diet (3), especially excessive intake of foods containing N-nitroso compounds, and patients often being at the advanced stage at the time of diagnosis, the prognosis for GC is often poor (4). Therefore, the study of malignant transformation of gastric cancer is extremely important to prevent the occurrence of GC.…”

A systematic review and meta-analysis on the efficacy of Compound Kushen Injection in 3 kinds of digestive tract tumor

“…At the time of diagnosis, most patients are in the middle and advanced stage and have exceeded the optimal surgical window of opportunity. Chemotherapy has become the main means to prolong the patient's life (2). Although chemotherapy can kill cancer cells and control clinical symptoms, it also destroys normal cells and tissues and brings toxic side effects, and some patients have to cease treatment due to inability to tolerate the side effects of chemotherapy (3).…”

Multiple roles of THY1 in gastric cancer based on data mining

“…Nowadays, the application of effective tumor biomarkers has become one of hot issues in the field of cancer research, and is associated with the patient’s quality of life and survival outcomes ( 12 , 13 ). THY1 has been identified over-expressed on the cytoplasmic membrane in several cell types.…”